City of Hope | Strategic Alliance Partners

December 11, 2023

In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.

December 10, 2023

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

December 09, 2023

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

December 05, 2023

Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study investigating lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma.

December 04, 2023

In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.

December 01, 2023

This commentary examines the use of words and expressions in the oncology domain and the implications of different interpretations by patients and their families from professionals employing this language, including academic authors and members of their clinical teams.

November 27, 2023

In this fifth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss the need for evidence to support the utilization of different artificial intelligence tools in healthcare.

November 24, 2023

Maurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.

November 20, 2023

In this fourth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain the importance of having a diverse editorial board behind a new journal on artificial intelligence in precision oncology.

November 13, 2023

In this third episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss the launch of a new journal that will focus on educating the field on the latest research efforts being made with artificial intelligence.

November 09, 2023

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

November 06, 2023

In this second episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools may be leveraged in the oncology field to provide personalized care.

November 06, 2023

It is time for society to address the critical nature of our current unsustainable oncology pharmaceutical marketplace, and it is also essential that whatever solutions are proposed and implemented do not incorporate inappropriate labeling of outcomes that negate meaningful measures of clinical benefit.

October 30, 2023

In this first episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, define artificial intelligence and highlight the goals of these tools in healthcare.

October 25, 2023

It is difficult to browse a major medical journal these days and not find an article, commentary, or editorial that discusses the objectively rather profound implications for clinical science and health care delivery resulting from simply stunning advances in computer technology in the arena of artificial intelligence.

October 13, 2023

Maurie Markman, MD, highlights the rather profound fiscal implications of the combined effect of 2 quite different but closely related components of the rapidly evolving cancer treatment paradigm.

October 10, 2023

In this final episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, reiterate that the role of endoscopic therapies in pancreatic cancer continues to evolve.

October 04, 2023

Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.

October 03, 2023

In this sixth episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, briefly discuss pancreatic cancer ablation and immune modulation.

October 02, 2023

Treatment with the first-in-class menin inhibitor revumenib generated complete remissions or complete remissions with partial hematological recovery in adult and pediatric patients with relapsed/refractory acute myeloid leukemia or acute lymphoblastic leukemia harboring KMT2A rearrangements.